- Home
- TEN vs PHAR Comparison
TEN vs PHAR Comparison
Compare TEN & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEN
- PHAR
- Stock Information
- Founded
- TEN 1993
- PHAR 1988
- Country
- TEN Greece
- PHAR Netherlands
- Employees
- TEN N/A
- PHAR N/A
- Industry
- TEN
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- TEN
- PHAR Health Care
- Exchange
- TEN NYSE
- PHAR Nasdaq
- Market Cap
- TEN 531.7M
- PHAR 627.5M
- IPO Year
- TEN N/A
- PHAR N/A
- Fundamental
- Price
- TEN $16.91
- PHAR $8.50
- Analyst Decision
- TEN Buy
- PHAR Strong Buy
- Analyst Count
- TEN 2
- PHAR 3
- Target Price
- TEN $31.00
- PHAR $27.00
- AVG Volume (30 Days)
- TEN 430.9K
- PHAR 7.3K
- Earning Date
- TEN 11-26-2024
- PHAR 10-24-2024
- Dividend Yield
- TEN 11.03%
- PHAR N/A
- EPS Growth
- TEN N/A
- PHAR N/A
- EPS
- TEN 5.46
- PHAR N/A
- Revenue
- TEN $836,042,000.00
- PHAR $285,745,000.00
- Revenue This Year
- TEN N/A
- PHAR $20.89
- Revenue Next Year
- TEN $10.35
- PHAR $11.15
- P/E Ratio
- TEN $3.02
- PHAR N/A
- Revenue Growth
- TEN N/A
- PHAR 30.64
- 52 Week Low
- TEN $15.88
- PHAR $6.65
- 52 Week High
- TEN $31.48
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- TEN 26.60
- PHAR 53.32
- Support Level
- TEN $15.88
- PHAR $8.71
- Resistance Level
- TEN $19.16
- PHAR $9.59
- Average True Range (ATR)
- TEN 0.64
- PHAR 0.33
- MACD
- TEN -0.06
- PHAR 0.11
- Stochastic Oscillator
- TEN 24.39
- PHAR 51.03
About TEN TSAKOS ENERGY NAVIGATION
Tsakos Energy Navigation Ltd is a seaborne transportation service provider for crude oil and petroleum products. The company's carriers cater to national and international independent oil companies and refiners. It generates revenue through charter contracts with its clients, which include time, bareboat, and voyage charters, contracts of affreightment, and pool arrangements.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.